NCT05026723

Brief Summary

This is a single-site, open-label, Phase II, community-based randomized controlled explanatory trial to test the efficacy of a medically tailored meal + intensive lifestyle intervention (MTM + ILI) intervention for adults with food insecurity, HIV, and T2DM or high risk of T2DM, compared with a group that receives usual MTM.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable diabetes-mellitus-type-2

Timeline
9mo left

Started Oct 2021

Longer than P75 for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
Oct 2021Feb 2027

First Submitted

Initial submission to the registry

August 23, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 30, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

October 4, 2021

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

December 11, 2025

Status Verified

December 1, 2025

Enrollment Period

4.8 years

First QC Date

August 23, 2021

Last Update Submit

December 5, 2025

Conditions

Keywords

Food InsecuritySocioeconomic FactorsLifestyle Intervention

Outcome Measures

Primary Outcomes (1)

  • Bodyweight at Month 6

    Bodyweight measured in Kg

    6 months

Secondary Outcomes (14)

  • Bodyweight at Month 12

    12 months

  • Bodyweight at Month 18

    18 months

  • Hemoglobin A1c at Month 6

    6 months

  • Hemoglobin A1c at Month 12

    12 months

  • Hemoglobin A1c at Month 18

    18 months

  • +9 more secondary outcomes

Other Outcomes (42)

  • Food Insecurity Score at Month 6

    6 Months

  • Food Insecurity Score at Month 12

    12 Months

  • Food Insecurity Score at Month 18

    18 Months

  • +39 more other outcomes

Study Arms (2)

Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI)

EXPERIMENTAL

The Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.

Behavioral: MTM + ILI

Standard MTM

ACTIVE COMPARATOR

The Standard Medically Tailored Meal (MTM) intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian.

Behavioral: Standard MTM

Interventions

MTM + ILIBEHAVIORAL

Weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program

Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI)
Standard MTMBEHAVIORAL

Weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian

Standard MTM

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female
  • Diagnosis of HIV
  • Diagnosis of Type 2 Diabetes Mellitus or high risk for type 2 diabetes mellitus, defined as meeting CDC eligibility criteria for the diabetes prevention program. Specifically, an individual without a diagnosis of T2DM must 1) have had a blood test result in the prediabetes range within the past year (Hemoglobin A1C: 5.7-6.4% OR Fasting plasma glucose: 100-125 mg/dL OR Two-hour plasma glucose \[after a 75 g glucose load\]: 140-199 mg/dL), 2) Have been previously diagnosed with gestational diabetes, OR 3) have a high-risk result (score of 5 or higher) on the Prediabetes Risk Test (https://www.cdc.gov/prediabetes/pdf/Prediabetes-Risk-Test-Final.pdf)
  • Experiencing food insecurity as indicated by 2-item Hunger Vital Sign
  • English speaking
  • Aged ≥18 years
  • BMI ≥ 23 kg/m2
  • No plans to move from the area for at least 1 year
  • Free living to the extent that participant has control over dietary intake
  • Willing and able to provide written informed consent and participate in all study activities

You may not qualify if:

  • Participant in diabetes, nutrition, or weight research intervention in last 12 months
  • Current AIDS defining illness
  • Another family member or household member is a study participant. Only one member of each household may take part in this study.
  • Considering bariatric surgery in the next year or prior bariatric surgery in the past 2 years
  • Lack of safe, stable residence and ability to store meals
  • Lack of telephone
  • Pregnancy/breastfeeding or intended pregnancy in the next year
  • History of malignancy, other than non-melanoma skin cancer, unless surgically or medically cured \> 5 years ago or in remission. Patients with localized prostate and breast cancer diagnosed during the course of routine screening will not be excluded.
  • Advanced kidney disease (estimated creatinine clearance \< 30 ml/min)
  • Known drug or alcohol misuse in the past 6 months
  • Known psychosis or major psychiatric illness that prevents participation with study activities
  • Intermittent use of medications (e.g., oral or intravenous glucocorticoids) that are likely to affect blood sugar

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 2HIV InfectionsPrediabetic State

Interventions

myotubularin

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Officials

  • Seth A Berkowitz, MD, MPH

    University of North Carolina, Chapel Hill

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Katharine Ricks, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Owing to the nature of the intervention, participants, providers, and many study staff will know to which group individual participants have been randomized. However, efforts will be made to keep the study statistician and outcome assessors blinded to randomization group during the course of the trial.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants will be assigned in 1:1 ratio to one of two intervention arms
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 23, 2021

First Posted

August 30, 2021

Study Start

October 4, 2021

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

February 1, 2027

Last Updated

December 11, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will share

Individual participant data (IPD) that can be deidentified without risk of confidentiality breach will shared upon written request made to study investigators. In addition, all NIH policies regarding data sharing will be followed. Deidentified individual data that supports the results will be shared provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina at Chapel Hill (UNC).

Shared Documents
STUDY PROTOCOL, ICF, ANALYTIC CODE
Time Frame
Unless preempted by NIH policy, data will become available 12 months after publication of main findings, and be available for 60 months.
Access Criteria
Unless otherwise required by NIH policy, ability to deidentify data, plan for secure storage of data and agreement to protect participant privacy, and relevant research question, to be assessed by study investigators.

Locations